Reminyl (galantamine hydrobromide) Tablets & Suspension, Johnson & Johnson Pharmaceutical Research & Development, L.L.C. NDA 21-169/S-007 & 21-224/S-005 1/30/03 9/9/03 Reminyl (galantamine hydrobromide) Tablets & Suspension, Johnson & Johnson Pharmaceutical Research & Development, L.L.C. NDA 21-169/S-003 & 21-224/S-003 4/19/02 5/2/02 Reminyl (galantamine hydrobromide) Solution, Janssen Research Foundation NDA 21-224 6/22/01 11/6/01 11/6/01 3/5/02 Reminyl (galantamine hydrobromide) Tablets, Janssen Research Foundation NDA 21-169 2/28/01 4/9/01 8/16/01 12/18/01 Reminyl Indications: The treatment of mild to moderate dementia of the Alzheimer's type. | Reminyl (galantamine hydrobromide) Extended Release Capsules, Johnson & Johnson, Approval | Galantamine Hydrobromide Tablets, J & J Pharma, Labeling Revision | Galantamine Hydrobromide Oral Solution, J & J Pharma, Labeling Revision | Galantamine Hydrobromide Extended-Release Capsules, J & J Pharma, Labeling Revision

For the most up-to-date approval information, please locate this API using the drug index. For industry specific content, please visit USActives.com.